UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended May 3, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________________ to _____________________ Commission File Number: 001-38026 J.Jill, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 45- ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended May 3, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ____________ Commission file number 0-23071 THE CHILDREN'S PLACE, INC. (Exact name of registrant as specified in its charter) D ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10−Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to _____________ Commission File Number: 001-41290 SMART FOR LIFE, INC. (Exact name of registrant as specified in its charter) (State or oth ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________ FORM 10-Q ___________________________ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended May 3, 2025 OR 12420 Stonebridge Road, Roanoke, Indiana 46783 (Address of principal executive offices) (Zip Code) (I.R.S. Employer Identification No.) ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF ...

Exhibit 99.1 DoubleVerify Reports First Quarter 2025 Financial Results Increased Revenue by 17% Year-over-Year to $165.1 Million Increased First Quarter Activation Revenue by 20% and Supply-Side Revenue by 35% Year-over-Year Achieved Net Income of $2.4 Million and Adjusted EBITDA of $44.7 Million, representing a 27% Adjusted EBITDA margin NEW YORK – May 8, 2025 – DoubleVerify ("DV") (NYSE: DV), the leading software platform for digital media measurement, data, and analytics, today announced financial result ...

First quarter consolidated net revenues totaled $51.7 million Financial condition remains strong with $86 million in liquidity and no debt FORT WAYNE, Ind., June 11, 2025 – Vera Bradley, Inc. (Nasdaq: VRA) today announced its financial results for the first quarter of the fiscal year ending January 31, 2026 ("Fiscal 2026"). First Quarter Comments VERA BRADLEY ANNOUNCES FIRST QUARTER FISCAL YEAR 2026 RESULTS For the current year first quarter, Vera Bradley, Inc.'s net loss from continuing operations totaled ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly report pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended April 30, 2025. or ☐ Transition report pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934. Commission File Number: 000-55863 RAFAEL HOLDINGS, INC. (Exact name of registrant as specified in its charter) | Delaware | 82-2296593 | | --- | --- | | (State or other jurisdiction of | (I.R.S. Emp ...

Financial Performance - Net sales for the 13 weeks ended May 4, 2025, were $3,116.0 million, an increase of 8.3% compared to $2,877.7 million for the same period in 2024[90]. - Net income decreased to $62.4 million, down 6.7% from $66.9 million in the prior year, resulting in a net margin of 2.0%[90]. - Adjusted EBITDA rose to $192.7 million, reflecting an 18.3% increase from $162.9 million in the previous year, with an adjusted EBITDA margin of 6.2%[90]. - Adjusted net income for the quarter was $148.9 million, an 8.6% increase from $137.1 million in the prior year[99]. - Adjusted basic earnings per share increased by 12.5% to $0.36, while adjusted diluted earnings per share rose by 12.9% to $0.35[99]. Customer Metrics - Active customers increased by 3.8% to 20.756 million, compared to 19.988 million in the prior year[90]. - Net sales per active customer grew by 3.7% to $583, up from $562 in the same period last year[90]. - Autoship customer sales reached $2,562.7 million, a 14.8% increase from $2,232.9 million, representing 82.2% of net sales[90]. - Active customers increased by 3.8% to 20.8 million, contributing to net sales growth of 8.3%, reaching $3.1 billion compared to $2.9 billion in the prior year[119]. - Net sales per active customer rose by $21 to $583, driven by growth in healthcare, specialty, and hardgoods businesses[119]. Expenses and Costs - Cost of goods sold increased by 8.3% to $2.2 billion, consistent with the increase in net sales, reflecting higher product and shipping supply costs[120]. - Gross profit for the period was $923.8 million, an increase of 8.2%, with a gross margin of 29.6%, slightly down from 29.7% in the previous year[121]. - Selling, general and administrative expenses rose by 8.4% to $653.1 million, primarily due to expansion costs in fulfillment operations and pharmacy networks[122]. - Advertising and marketing expenses increased by 3.7% to $193.8 million, with expectations for these expenses to be approximately 6.7 to 6.8 percent of net sales for the fiscal year[124]. Cash Flow and Investments - Free cash flow decreased to $48.7 million, down 7.4% from $52.6 million in the previous year[90]. - Free cash flow for the thirteen weeks ended May 4, 2025, was $48.7 million, a decrease from $52.6 million for the same period in 2024, with net cash provided by operating activities at $86.4 million[104]. - Net cash provided by operating activities for the thirteen weeks ended May 4, 2025, was $86.4 million, an increase from $81.9 million for the same period in 2024[129][130]. - Net cash used in investing activities was $41.2 million for the thirteen weeks ended May 4, 2025, primarily for capital expenditures of $37.7 million related to expanding operations[132]. - Net cash used in financing activities was $25.0 million for the thirteen weeks ended May 4, 2025, mainly for repurchases of common stock totaling $23.1 million[134]. Financial Position - Cash and cash equivalents totaled $616.4 million as of May 4, 2025, reflecting an increase of $20.6 million from February 2, 2025[127]. - The company has a senior secured asset-based credit facility with a borrowing capacity of $782.8 million as of May 4, 2025, with no outstanding borrowings[136]. - The Board of Directors authorized a share repurchase program of up to $500 million, with $383.5 million remaining available for repurchase as of May 4, 2025[137][138]. - The ABL Credit Facility matures on April 1, 2030, and allows for incremental commitments of up to $250 million[136]. Operational Adjustments - The company continues to adapt its logistics and supply chain processes in response to evolving macroeconomic conditions, including inflation and high interest rates[86]. - The company is modernizing its finance information technology architecture to enhance scalability and analytical capabilities, expected to conclude by the end of the 2025 fiscal year[123]. - Non-cash adjustments in operating activities included share-based compensation expense of $74.5 million and depreciation and amortization expense of $30.0 million for the thirteen weeks ended May 4, 2025[130]. - Working capital changes for the thirteen weeks ended May 4, 2025, resulted in a cash decrease of $88.8 million, primarily due to a decrease in accrued expenses and an increase in accounts receivable[130]. Previous Year Comparison - The company reported a net income of $62.4 million for the thirteen weeks ended May 4, 2025, compared to $66.9 million for the same period in 2024[130][131]. - Interest income decreased by $11.3 million to $3.2 million, attributed to lower income from marketable securities[125]. - The company experienced a significant cash inflow of $505.7 million from investing activities for the thirteen weeks ended April 28, 2024, primarily from the maturities of marketable securities[133].

"We are pleased to have completed our merger with Cyclo Therapeutics and look forward to reporting the topline data from the 48- week interim analysis of the pivotal Phase 3 TransportNPC™ study evaluating Trappsol Cyclo™ for the treatment of Niemann-Pick Disease Type C1 anticipated later this month," said Howard Jonas, Chief Executive Officer, Executive Chairman and Chairman of the Board of Rafael Holdings. Mr. Jonas added, "We have enhanced our financial position with the closing of a $25 million rights of ...

Financial Performance - Net sales for Q1 2025 reached $3.12 billion, an increase of 8.3% year-over-year[7] - Gross margin was 29.6%, a decrease of 10 basis points year-over-year[7] - Net income amounted to $62.4 million, with a net margin of 2.0%, down 30 basis points year-over-year[7] - Adjusted EBITDA was $192.7 million, reflecting an increase of $29.8 million year-over-year, with an adjusted EBITDA margin of 6.2%, up 50 basis points[7] - Net sales for the 13 weeks ended May 4, 2025, were $3,116.0 million, an increase of 8.3% compared to $2,877.7 million for the same period in 2024[18] - Net income decreased to $62.4 million, down 6.7% from $66.9 million year-over-year[18] - Adjusted EBITDA rose to $192.7 million, reflecting an 18.3% increase from $162.9 million in the prior year[18] - Adjusted net income increased to $148.9 million, an 8.6% rise from $137.1 million year-over-year[27] Customer Metrics - Active customer growth was reported, contributing to the overall sales momentum[4] - Active customers increased by 3.8% to 20.756 million, up from 19.988 million in the previous year[18] - Autoship customer sales reached $2,562.7 million, a 14.8% increase compared to $2,232.9 million in the previous year[18] Cash Flow and Liquidity - Cash and cash equivalents increased to $616.4 million from $595.8 million as of February 2, 2025[12] - Cash and cash equivalents at the end of the period were $616.4 million, down from $1,134.6 million at the end of the same period last year[16] - Free cash flow for the period was $48.7 million, a decrease of 7.4% from $52.6 million in the same quarter last year[18] - Free cash flow for the 13 weeks ended May 4, 2025, was $48.7 million, down from $52.6 million for the same period in 2024, reflecting a decrease of approximately 7.4%[31] - Net cash provided by operating activities was $86.4 million, representing a 5.5% increase from $81.9 million in the prior year[18] - Net cash provided by operating activities increased to $86.4 million for the 13 weeks ended May 4, 2025, compared to $81.9 million for the same period in 2024, representing an increase of about 5.5%[31] Assets and Liabilities - Total assets rose to $3,060.3 million, compared to $3,014.5 million as of February 2, 2025[12] - Total liabilities decreased slightly to $2,684.7 million from $2,753.0 million[12] Strategic Initiatives - The company aims to continue expanding its market share in the pet category, leveraging its value proposition[4] - The company plans to introduce new products and services while expanding into new jurisdictions[9] - The company is investing in new fulfillment centers, pharmacy facilities, veterinary clinics, and customer service infrastructure, which may affect future cash flow[31] - Capital expenditures for the 13 weeks ended May 4, 2025, were $37.7 million, up from $29.3 million in the same period in 2024, indicating an increase of approximately 28.5%[31] - The company anticipates that free cash flow may be impacted by the timing of capital investments, fluctuations in growth, and changes in working capital[31]